Trade Names:Menactra- Injection 48 mcg
Trade Names:Menomune-A/C/Y/W-135- Injection 50 mcg
Induces production of bactericidal antibodies specific to capsular polysaccharides of serogroups A, C, Y, and W-135.
Active immunization of children and adults 2 to 55 yr of age against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
MenomuneActive immunization against invasive meningococcal disease caused by serogroups A, C, Y, and W-135; may be used to prevent and control outbreaks of serogroup C meningococcal disease.
Hypersensitivity to dry natural rubber latex; hypersensitivity to any component of the product, including diphtheria toxoid; known history of Guillain-Barré syndrome; life-threatening reaction after previous administration of a vaccine containing similar components.
MenomuneKnown sensitivity to thimerosal or any component of the vaccine. Defer immunization during any acute illness.
IM Single 0.5 mL dose, preferably in the deltoid region.
MenomuneAdults and children 2 yr of age and olderSubcutaneous Single 0.5 mL dose. Revaccination with a single 0.5 mL dose may be indicated for persons at high risk of infection, particularly children who were first vaccinated when they were younger than 4 yr of age.
Store vials in refrigerator (36° to 46°F). Protect from freezing. Do not use vaccine if it has been frozen.
MenomuneStore at 35° to 46°F. Discard remainder of multidose vials within 35 days of reconstitution. Use single-dose vial within 30 min after reconstitution.
An adequate immunologic response may not be obtained.
Whole-cell pertussis, whole-cell typhoid vaccinesDo not coadminister with Menomune because of combined endotoxin content.
None well documented.
Headache (42%); fatigue (35%); malaise (24%); irritability (12%); drowsiness (11%); acute disseminated encephalomyelitis, facial palsy, Guillain-Barré Syndrome, transverse myelitis, vasovagal syncope (postmarketing).
Rash (3%); urticaria (postmarketing).
Diarrhea (16%); anorexia (12%); vomiting (3%).
Pain (59%); tenderness (36%); redness (22%); induration (19%); swelling (17%); erythema (4%).
Arthralgia (20%); myalgia (postmarketing).
Chills (10%); fever (5%).
Category C .
Undetermined.
Safety and efficacy not established in children younger than 2 yr of age.
Safety and efficacy not established in adults older than 55 yr of age.
Vaccine and vaccine components can cause hypersensitivity reactions.
Risk of Guillain-Barré Syndrome following Menactra vaccination may be increased. Persons with a history of Guillain-Barré Syndrome should not receive Menactra vaccine.
Dry natural latex rubber is contained in the vial stopper.
Copyright © 2009 Wolters Kluwer Health.